Groundbreaking Trial Launches for Novel Antibody Drug M1231 Against Advanced Tumors
A groundbreaking clinical trial is underway in Texas and Canada, testing a novel antibody-based medication, M1231, for treating advanced tumors. This innovative drug, developed over two decades, is a bispecific antibody drug conjugate (ADC) that targets and fights cancer cells more effectively than existing antibody-based drugs.
M1231, an invention from the Technical University of Brunswick, utilizes a human antibody that specifically targets tumor cells. It is a bispecific antibody with two 'arms' that recognize two different features on cancer cells. One arm is based on the cancer medication Erbitux, while the other is a novel invention from the university. After binding to cancer cells, M1231 activates the body's own immune system against the tumor and releases the cancer-fighting drug directly into the tumor. The clinical trial, NCT04695847, is investigating the safety of M1231 for patients with metastatic solid tumors, esophageal cancer, and non-small cell lung cancer. This is the first time such an antibody-based medication is being clinically tested on patients with advanced tumors in the USA. The trial is expected to run until July 2023 and is conducted by the pharmaceutical company Jiangsu Hengrui Medicine Co., Ltd.
M1231, with its improved multiple targeting and fighting functions, offers hope for more effective cancer treatment. The ongoing clinical trial aims to establish its safety and pave the way for further advancements in cancer therapy.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
